Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Safiyyah Ziyad, Kristina Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry Anderson, Tara Gregory, Luciano Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison Kaeding, Shari Kaiser, Michael Burgess, Jesús Berdeja

Blood (2025) 146 (Supplement 1): 2223.

https://doi.org/10.1182/blood-2025-2223

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

Lauren Merz, Sabine Allam, Sungjae Kim, Jean-Baptiste Alberge, Jacqueline Perry, David Lee, Katherine Padgett, Julia Colchie, Omar Nadeem, Irene Ghobrial, Paul Richardson

Blood (2025) 146 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2025-4578

Published: 2025

Journal Articles

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2025-2182

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Susan Bal, Luciano Costa, Nizar Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safiyyah Ziyad, Sham Mailankody

Blood (2025) 146 (Supplement 1): 5807.

https://doi.org/10.1182/blood-2025-5807

Published: 2025

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Blood (2025) 146 (Supplement 1): 827.

https://doi.org/10.1182/blood-2025-827

Published: 2025

Journal Articles

Optimizing fludarabine: The impact of fludarabine renal dose adjustment during lymphodepletion prior to CAR-T cell immunotherapy in multiple myeloma patients

Lara Abousamra, Sylvia Truong, Houry Leblebjian, Robert Redd, Omar Nadeem

Blood (2025) 146 (Supplement 1): 826.

https://doi.org/10.1182/blood-2025-826

Published: 2025

Journal Articles

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Blood (2025) 146 (Supplement 1): 825.

https://doi.org/10.1182/blood-2025-825

Published: 2025

Journal Articles

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5824.

https://doi.org/10.1182/blood-2025-5824

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Blood (2025) 146 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2025-3930

Published: 2025

Journal Articles

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Blood (2025) 146 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2025-3921

Published: 2025

Journal Articles

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Blood (2025) 146 (Supplement 1): 261.

https://doi.org/10.1182/blood-2025-261

Published: 2025

Journal Articles

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Zohaib Ahmed, Walid Hamouche, Shonali Midha, Yuxin Liu, Adam Sperling, Clifton Mo, Jacob Laubach, Paul Richardson, Nikhil Munshi, Omar Nadeem

Blood (2025) 146 (Supplement 1): 7525.

https://doi.org/10.1182/blood-2025-7525

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Blood (2025) 146 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2025-4079

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Optimizing fludarabine: The impact of fludarabine renal dose adjustment during lymphodepletion prior to CAR-T cell immunotherapy in multiple myeloma patients

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only